Article Details
Retrieved on: 2023-12-04 16:48:07
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The biotech said Phase 2 study results showed its experimental medicine for age-related macular degeneration was “non-inferior” to Regeneron's Eylea.
Article found on: www.biopharmadive.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here